Cingulate reports $22.4M FY2025 net loss, CTx-1301 patent allowed, PDUFA May 2026

Cingulate Inc.

Net loss of $22.4M for 2025 vs $16.6M in 2024; Q4 net loss $6.3M.
Cash $11.0M at Dec 31, 2025; expects runway into late Q4 2026.
USPTO Notice of Allowance for CTx-1301 patent; protection through May 2042.
NDA for CTx-1301 accepted under 505(b)(2); PDUFA target date May 31, 2026.
Closed $12M at-the-market PIPE in Feb 2026 led by Falcon Creek Capital; 180-day lock-up.

item 2.02 item 8.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.8

Cingulate Inc. reported financial results for the year ended December 31, 2025.

Period: the year ended December 31, 2025
Result: reported results

Exact text from the filing

On March 18, 2026, Cingulate Inc. issued a press release announcing its financial results for the year ended December 31, 2025 and providing a business update.

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.8

Cingulate Inc. reported financial results for the quarter ended December 31, 2025.

Period: the quarter ended December 31, 2025
Result: reported results

Exact text from the filing

today reported financial results for the quarter ended December 31, 2025, and provided a corporate update.

View on SEC.gov

51 earnings releases filed in the last 30 days. Browse all earnings releases →

Cingulate Inc. filing history →

Source: SEC EDGAR

accession 0001493152-26-010881

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.